Actinium Pharmaceuticals, Inc. (ATNM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 400K 800K 1.2M FY10: 0 FY11: 0 FY21: 1.1M FY22: 1M FY23: 81K FY25: 90K FY10 FY11 FY21 FY22 FY23 FY25

Gross Profit Annual

0 FY10: 0 FY11: 0 FY10 FY11

Operating Income Annual

-60M -40M -20M 0 20M 40M 60M FY10: -26.1K FY11: -3.3M FY12: -7.9M FY13: -6.6M FY14: -22.5M FY15: -24.8M FY16: -26.8M FY17: -26.9M FY18: -23.8M FY19: -22.1M FY20: -22.4M FY21: -25M FY22: -34.1M FY23: -51.9M FY24: -42.1M FY25: -36.2M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-60M -40M -20M 0 20M 40M 60M FY01: -5.1M FY02: -3.2M FY03: -3.5M FY04: -5.7M FY05: -4.6M FY06: -6.1M FY07: -5.6M FY08: -5.6M FY09: -3.4M FY10: -467.3K FY11: -3.4M FY12: -8.4M FY13: -10.8M FY14: -24.7M FY15: -21M FY16: -24.3M FY17: -26.6M FY18: -23.7M FY19: -21.9M FY20: -22.2M FY21: -24.8M FY22: -33M FY23: -48.8M FY24: -38.2M FY25: -33.9M FY01 FY04 FY07 FY10 FY13 FY16 FY19 FY22 FY25

Cost of Revenue Annual

0 350K 700K 1.1M FY21: 900K FY21

Operating Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY10: 7.8K FY11: -517.6K FY12: -5.2M FY13: -6.3M FY14: -14.3M FY15: -18.5M FY16: -20.8M FY17: -21.6M FY18: -20.6M FY19: -21.5M FY20: -21.6M FY21: -20.9M FY22: 8.6M FY23: -47.3M FY24: -33.1M FY25: -24.6M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY12: -5.2M FY13: -6.3M FY14: -14.5M FY15: -18.6M FY16: -20.8M FY17: -21.6M FY18: -20.7M FY19: -21.5M FY20: -21.9M FY21: -21M FY22: 8.3M FY23: -47.5M FY24: -33.1M FY25: -24.7M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 15M 30M 45M FY21: 20.6M FY22: 24.1M FY23: 26.6M FY24: 30.1M FY25: 31.2M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q2 '12: -0.17 Q3 '12: -3.93 Q4 '12: -4.66 Q1 '13: -4.62 Q2 '13: -4.66 Q3 '13: -0.96 Q4 '13: -0.47 Q1 '14: -1.10 Q2 '14: -0.87 Q3 '14: -1.02 Q4 '14: -0.94 Q1 '15: -0.37 Q2 '15: -0.67 Q3 '15: -0.56 Q4 '15: -0.55 Q1 '16: -0.56 Q2 '16: -0.51 Q3 '16: -0.55 Q4 '16: -0.51 Q1 '17: -0.55 Q2 '17: -0.52 Q3 '17: -0.47 Q4 '17: -0.41 Q1 '18: -0.34 Q2 '18: -0.26 Q3 '18: -0.23 Q4 '18: -0.22 Q1 '19: -0.20 Q2 '19: -1.16 Q3 '19: -2.31 Q4 '19: -3.06 Q1 '20: -3.99 Q2 '20: -3.40 Q3 '20: -2.55 Q4 '20: -2.12 Q1 '21: -1.43 Q2 '21: -1.27 Q3 '21: -1.21 Q4 '21: -1.20 Q1 '22: -1.14 Q2 '22: -1.22 Q3 '22: -1.30 Q4 '22: -1.37 Q1 '23: -1.57 Q2 '23: -1.82 Q3 '23: -1.93 Q4 '23: -1.83 Q1 '24: -1.71 Q2 '24: -1.51 Q3 '24: -1.39 Q4 '24: -1.27 Q1 '25: -1.47 Q2 '25: -1.31 Q3 '25: -1.10 Q4 '25: -1.08 Q1 '26: -0.75 Q2 '26: 0.36 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.